Cytori Therapeutics, Inc. (NASDAQ:CYTX) shares fell 2.6% during trading on Wednesday . The stock traded as low as $0.32 and last traded at $0.38. 294,000 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 769,212 shares. The stock had previously closed at $0.39.

Several research firms recently commented on CYTX. B. Riley restated a “neutral” rating on shares of Cytori Therapeutics in a report on Sunday, July 30th. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Friday, August 11th. Zacks Investment Research lowered shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, ValuEngine lowered shares of Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 271.12% and a negative return on equity of 202.43%. The company had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. During the same quarter last year, the company earned ($0.26) earnings per share. analysts predict that Cytori Therapeutics, Inc. will post -0.62 earnings per share for the current year.

A number of large investors have recently modified their holdings of CYTX. Perkins Capital Management Inc. grew its position in Cytori Therapeutics by 99.0% in the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock valued at $962,000 after acquiring an additional 435,217 shares in the last quarter. Sabby Management LLC grew its position in shares of Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after buying an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after buying an additional 275,653 shares in the last quarter. 12.02% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/17/cytori-therapeutics-inc-cytx-stock-price-down-2-6.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Stock Ratings for Cytori Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc. and related stocks with our FREE daily email newsletter.